{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:55:29Z","timestamp":1785585329130,"version":"3.56.0"},"reference-count":13,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>This Policy Statement was retired April 2025.<\/jats:title>\n               <jats:p>This statement updates the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2022\u20132023 influenza season. A detailed review of the evidence supporting these recommendations is published in the accompanying technical report (http:\/\/www.pediatrics.org\/cgi\/doi\/10.1542\/peds.2022-059275). The American Academy of Pediatrics recommends annual influenza vaccination of all children without medical contraindications starting at 6 months of age. Influenza vaccination is an important strategy for protecting children and the broader community, as well as reducing the overall burden of respiratory illnesses when other viruses, including severe acute respiratory syndrome-coronavirus 2, are cocirculating. Any licensed influenza vaccine appropriate for age and health status can be administered, ideally as soon as possible in the season, without preference for one product or formulation over another.<\/jats:p>\n               <jats:p>Antiviral treatment of influenza with any US Food and Drug Administration-approved, age-appropriate influenza antiviral medication is recommended for children with suspected or confirmed influenza who are hospitalized, have severe or progressive disease, or have underlying conditions that increase their risk of complications of influenza, regardless of duration of illness. Antiviral treatment should be initiated as soon as possible. Antiviral treatment may be considered in the outpatient setting for symptomatic children with suspected or confirmed influenza disease who are not at high risk for influenza complications, if treatment can be initiated within 48 hours of illness onset, and for children with suspected or confirmed influenza disease whose siblings or household contacts either are younger than 6 months or have a high-risk condition that predisposes them to complications of influenza. Antiviral chemoprophylaxis is recommended for the prevention of influenza virus infection as an adjunct to vaccination in certain individuals, especially exposed children who are at high risk for influenza complications but have not yet been immunized or who lack a sufficient immune response.<\/jats:p>","DOI":"10.1542\/peds.2022-059274","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T13:13:11Z","timestamp":1662469991000},"source":"Crossref","is-referenced-by-count":28,"title":["Recommendations for Prevention and Control of Influenza in Children, 2022\u20132023"],"prefix":"10.1542","volume":"150","author":[{"name":"COMMITTEE ON INFECTIOUS DISEASES","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"2025072309471415900_B1","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2022-2023 influenza season","author":"Grohskopf","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"2025072309471415900_B2","doi-asserted-by":"crossref","first-page":"e20163690","DOI":"10.1542\/peds.2016-3690","article-title":"Pandemic influenza preparedness among child care center directors in 2008 and 2016","volume":"139","author":"Shope","year":"2017","journal-title":"Pediatrics"},{"key":"2025072309471415900_B3","unstructured":"Centers for Disease Control and Prevention\n          . Weekly flu vaccination dashboard. Available at: https:\/\/www.cdc.gov\/flu\/fluvaxview\/dashboard\/vaccination- dashboard.html. Accessed July 8, 2022"},{"issue":"4","key":"2025072309471415900_B4","doi-asserted-by":"crossref","first-page":"e2022059275","DOI":"10.1542\/peds.2022-059275","article-title":"Technical report. Recommendations for prevention and control of influenza in children, 2022\u20132023","volume":"150","author":"American Academy of Pediatrics, Committee on Infectious Diseases","year":"2022","journal-title":"Pediatrics"},{"key":"2025072309471415900_B5","unstructured":"World Health Organization\n          . Recommended composition of influenza virus vaccines for use in the 2022\u20132023 northern hemisphere influenza season. Available at: https:\/\/www.who.int\/publications\/m\/item\/recommended-composition- of-influenza-virus-vaccines-for-use-in- the-2022-2023-northern-hemisphere- influenza-season. Accessed March 31, 2022"},{"key":"2025072309471415900_B6","unstructured":"United States Food and Drug Administration\n          . Vaccines and Related Biological Products Advisory Committee March 3, 2022, meeting announcement. Available at: https:\/\/www.fda.gov\/advisory- committees\/advisory-committee- calendar\/vaccines-and-related- biological-products-advisory-committee- march-3-2022-meeting-announcement. Accessed March 31, 2022"},{"key":"2025072309471415900_B7","article-title":"Clinical review: Flucelvax quadrivalent","author":"Food and Drug Administration","year":"2021"},{"key":"2025072309471415900_B8","unstructured":"US Food and Drug Administration\n          . Baloxavir package insert. Available at: https:\/\/www.gene.com\/download\/pdf\/xofluza_prescribing.pdf. Accessed August 22, 2022"},{"issue":"8","key":"2025072309471415900_B9","doi-asserted-by":"crossref","first-page":"e2121880","DOI":"10.1001\/jamanetworkopen.2021.21880","article-title":"Rates of influenza-associated hospitalization, intensive care unit admission, and in-hospital death by race and ethnicity in the United States from 2009 to 2019","volume":"4","author":"O\u2019Halloran","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025072309471415900_B10","unstructured":"United States Food and Drug Administration\n          . Vaccines licensed for use in the United States. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use- united-states. Accessed April 4, 2022"},{"issue":"4","key":"2025072309471415900_B11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jhep.2018.11.015","article-title":"Influenza virus infection as precipitating event of acute-on-chronic liver failure","volume":"70","author":"Sch\u00fctte","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"2025072309471415900_B12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jceh.2018.04.006","article-title":"A\/H1N1\/09 influenza is associated with high mortality in liver cirrhosis","volume":"9","author":"Premkumar","year":"2019","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"2025072309471415900_B13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2018 update diagnosis, treatment, chemoprophylaxis and institutional outbreak management of seasonal influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-059274\/1562065\/peds_2022059274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-059274\/1562065\/peds_2022059274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T13:47:20Z","timestamp":1753278440000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/150\/4\/e2022059274\/189385\/Recommendations-for-Prevention-and-Control-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,9,6]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2022-059274","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"article-number":"e2022059274"}}